Cell cycle specific antimetabolites mainly act on tumor cells in the DNA synthesis phase (S phase) and can prevent the progression from the G1 phase to the S phase. They are converted into active metabolites gemcitabine monophosphate (dFdCMP), gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) in cells. dFdCDP inhibits ribonucleotide reductase and reduces the amount of deoxynucleotides; dFdCTP competes with dCTP for binding to the DNA chain, inserts into the deoxycytidine site and prevents DNA chain synthesis, leading to DNA breakage and cell death.

It is a bifunctional alkylating agent belonging to the class of bismethyl sulfonates and is a non-specific drug for the cell cycle. When it enters the human body, the ring structure of the sulfonate group opens and destroys the structure and function of DNA by alkylating guanine in the cell's DNA. The cytotoxic effect of this product is almost entirely manifested in the inhibition of hematopoietic function, mainly manifested in the obvious inhibition of granulocyte production. The second is the inhibition of platelets and red blood cells, and the inhibition of lymphocytes is very weak.

It is a bifunctional alkylating agent belonging to the class of bismethyl sulfonates and is a non-specific drug for the cell cycle. When it enters the human body, the ring structure of the sulfonate group opens and destroys the structure and function of DNA by alkylating guanine in the cell's DNA. The cytotoxic effect of this product is almost entirely manifested in the inhibition of hematopoietic function, mainly manifested in the obvious inhibition of granulocyte production. The second is the inhibition of platelets and red blood cells, and the inhibition of lymphocytes is very weak.

It has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells.

Anti-tuberculosis drugs are a combination of rifampicin, isoniazid and pyrazinamide. Rifampicin has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae) both inside and outside the host cells.

Anti-tuberculosis drugs are a combination of rifampicin, isoniazid and pyrazinamide. Rifampicin has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae) both inside and outside the host cells.